[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566029":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":68,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Liver Transplant","EXPERIMENTAL","Subjects with liver disease with planned living donor liver transplantation",[13],"Drug: Autologous adipose derived mesenchymal stromal cells (AMSC)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Autologous adipose derived mesenchymal stromal cells (AMSC)","Adipose derived autologous mesenchymal stromal cells; \\[\\~500,000 cells\u002Fcm2\\] will be applied once to the biliary anastomosis using approximately 3-5 million cells in 5ml Lactated Ringer solution.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Julie Heimbach","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Jackie Reiter","CONTACT","507-538-2224","Reiter.Jacqulyn@mayo.edu",[32],{"facility":33,"status":20,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":20},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-92.4699,44.02163,{"lat":43,"lon":42},{"type":24,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Julie K. Heimbach","Principal Investigator","100566029","phase-1-adipose-derived-mesenchymal-stem-cell-for-preventing-biliary-complications-100566029",false,"NCT06649864","Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications","A Phase I Study of Autologous Adipose-derived Mesenchymal Stromal Cells in Preventing Biliary Complications After Living Donor Liver Transplant","Inclusion Criteria\n\n* Listed for liver transplantation\n* Non-pediatric patients with a planned LDLT\n* Ability to communicate with investigative staff\n* Competence to give written informed consent\n* Ability to comply with the entire study procedure\n* All sexes and genders will be eligible for the study\n\nExclusion Criteria\n\n* Planned deceased donor liver transplantation\n* Uncontrolled \u002F unresolved local or systemic infection\n* Body mass index \\> 40\n* Planned pancreaticoduodenectomy or sleeve gastrectomy\n* Anticipation of 3 biliary anastomoses (we will include those anticipated to have 1 or 2 biliary anastomoses as detailed below)\n* Pregnancy or breastfeeding\n* Non-liver cancers (we will include certain patients with primary liver cancer as detailed below)\n* Treatment with any investigational drug \u002F device within 60 days prior to study entry\n* Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and efficacy of AMSCs\n* Patients who are employees or relatives of the investigator","ALL","18 Years","65 Years",{"count":59,"type":60},20,"ESTIMATED","INTERVENTIONAL",[63],"PHASE1","The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver Transplantation.",[66,67],"Liver Transplant; Complications","Liver Diseases","NOT_YET_RECRUITING","2026-03-31",{"date":71,"type":72},"2026-04-06","ACTUAL",{"date":74,"type":60},"2027-02",{"date":76,"type":60},"2028-06",{"name":5,"class":6},1]